Fmr LLC Sutro Biopharma, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Fmr LLC holds 151,340 shares of STRO stock, worth $629,574. This represents 0.0% of its overall portfolio holdings.

Number of Shares

151,340

Previous 112,322 34.74%

Holding current value

$629,574

Previous $634,000 30.13%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.92 - $5.33 $113,932 - $207,965	39,018 Added 34.74%	151,340 $443,000
Q1 2024 May 13, 2024	BUY	$3.27 - $5.65 $87,423 - $151,052	26,735 Added 31.24%	112,322 $634,000
Q4 2023 Feb 13, 2024	BUY	$2.07 - $4.54 $11,026 - $24,184	5,327 Added 6.64%	85,587 $367,000
Q3 2023 Nov 13, 2023	BUY	$3.29 - $4.9 $2,467 - $3,675	750 Added 0.94%	80,260 $278,000
Q2 2023 Aug 11, 2023	SELL	$4.25 - $5.88 $17,272 - $23,896	-4,064 Reduced 4.86%	79,510 $369,000
Q1 2023 May 11, 2023	SELL	$4.48 - $8.45 $2.42 Million - $4.57 Million	-540,760 Reduced 86.61%	83,574 $386,000
Q4 2022 Feb 13, 2023	SELL	$5.41 - $8.08 $660,674 - $986,737	-122,121 Reduced 16.36%	624,334 $5.04 Million
Q3 2022 Nov 10, 2022	BUY	$5.17 - $7.11 $424,167 - $583,332	82,044 Added 12.35%	746,455 $4.14 Million
Q2 2022 Aug 12, 2022	SELL	$3.41 - $8.95 $249,850 - $655,766	-73,270 Reduced 9.93%	664,411 $3.46 Million
Q1 2022 May 13, 2022	BUY	$7.78 - $15.31 $2,964 - $5,833	381 Added 0.05%	737,681 $6.06 Million
Q2 2021 Aug 13, 2021	BUY	$18.03 - $23.82 $13.3 Million - $17.6 Million	737,300 New	737,300 $13.7 Million

Others Institutions Holding STRO

# of Institutions

128

Shares Held

62.3M

Call Options Held

200

Put Options Held

27.6K

View Full List

About SUTRO BIOPHARMA, INC.

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $217M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

More about STRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account